National Institute for Clinical Excellence (NICE) Recommends Bayer AG's Xarelto

Published: Jul 25, 2012

German chemical and pharmaceutical company Bayer AG (BAYN.XE) Wednesday said the U.K.'s regulator has confirmed its recommendation, allowing Xarelto to be used to treat blood clots. MAIN FACTS: -The ruling confirms draft guidance by the National Institute for Health and Clinical Excellence, known as NICE, at end-May. -Xarelto can now be used for the treatment of deep vein thrombosis and pulmonary embolism by the U.K.'s National Health Service. -"The NICE endorsement of Xarelto is a significant step forward in the evolution of deep vein thrombosis treatment," Dr. Kemal Malik, head of global development at Bayer HealthCare, said.

Back to news